Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $475.9 million.

  • Iovance Biotherapeutics' Non-Current Assets was N/A to $475.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $475.9 million, marking a year-over-year change of. This contributed to the annual value of $453.4 million for FY2024, which is 4.04% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Non-Current Assets stood at $475.9 million for Q3 2025, which was down 1.87% from $484.9 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Non-Current Assets' 5-year high stood at $484.9 million during Q2 2025, with a 5-year trough of $187.0 million in Q1 2023.
  • In the last 3 years, Iovance Biotherapeutics' Non-Current Assets had a median value of $472.5 million in 2023 and averaged $440.5 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Non-Current Assets skyrocketed by 159.00% in 2024, and later declined by 6.24% in 2025.
  • Iovance Biotherapeutics' Non-Current Assets (Quarterly) stood at $472.5 million in 2023, then decreased by 4.04% to $453.4 million in 2024, then dropped by 6.24% to $475.9 million in 2025.
  • Its Non-Current Assets was $475.9 million in Q3 2025, compared to $484.9 million in Q2 2025 and $454.1 million in Q1 2025.